OCA at 12:58, 1 February 2024

OCA — Thu, 01 Feb 2024 12:58:16 GMT

←Older revision		Revision as of 12:58, 1 February 2024
Line 1:		Line 1:

	==Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide==		==Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide==
-	<StructureSection load='7oxn' size='340' side='right'caption='[[7oxn]]' scene=''>	+	<StructureSection load='7oxn' size='340' side='right'caption='[[7oxn]], [[Resolution\|resolution]] 2.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7OXN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7OXN FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[7oxn]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7OXN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7OXN FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7oxn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7oxn OCA], [https://pdbe.org/7oxn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7oxn RCSB], [https://www.ebi.ac.uk/pdbsum/7oxn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7oxn ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.5Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SMC:S-METHYLCYSTEINE'>SMC</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7oxn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7oxn OCA], [https://pdbe.org/7oxn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7oxn RCSB], [https://www.ebi.ac.uk/pdbsum/7oxn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7oxn ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/A4_HUMAN A4_HUMAN] Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:[https://omim.org/entry/104300 104300]. AD1 is a familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.<ref>PMID:8476439</ref> <ref>PMID:15201367</ref> <ref>PMID:1671712</ref> <ref>PMID:1908231</ref> <ref>PMID:1678058</ref> <ref>PMID:1944558</ref> <ref>PMID:1925564</ref> <ref>PMID:1415269</ref> <ref>PMID:1303239</ref> <ref>PMID:1302033</ref> <ref>PMID:1303275</ref> <ref>PMID:8267572</ref> <ref>PMID:8290042</ref> <ref>PMID:8577393</ref> <ref>PMID:9328472</ref> <ref>PMID:9754958</ref> <ref>PMID:10097173</ref> <ref>PMID:10631141</ref> <ref>PMID:10665499</ref> <ref>PMID:10867787</ref> <ref>PMID:11063718</ref> <ref>PMID:11311152</ref> <ref>PMID:11528419</ref> <ref>PMID:12034808</ref> <ref>PMID:15365148</ref> <ref>PMID:15668448</ref> Defects in APP are the cause of cerebral amyloid angiopathy APP-related (CAA-APP) [MIM:[https://omim.org/entry/605714 605714]. A hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels. The principal clinical characteristics are recurrent cerebral and cerebellar hemorrhages, recurrent strokes, cerebral ischemia, cerebral infarction, and progressive mental deterioration. Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare and largely in the form of pre-amyloid lesions or diffuse plaque-like structures. They are Congo red negative and lack the dense amyloid cores commonly present in Alzheimer disease. Some affected individuals manifest progressive aphasic dementia, leukoencephalopathy, and occipital calcifications.<ref>PMID:10821838</ref> <ref>PMID:2111584</ref> <ref>PMID:11409420</ref> <ref>PMID:12654973</ref> <ref>PMID:16178030</ref>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/A4_HUMAN A4_HUMAN] Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.<ref>PMID:9168929</ref> <ref>PMID:11544248</ref> <ref>PMID:11943163</ref> <ref>PMID:19225519</ref> <ref>PMID:19901339</ref> Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with Also bind GPC1 in lipid rafts.<ref>PMID:9168929</ref> <ref>PMID:11544248</ref> <ref>PMID:11943163</ref> <ref>PMID:19225519</ref> <ref>PMID:19901339</ref> Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain (By similarity).<ref>PMID:9168929</ref> <ref>PMID:11544248</ref> <ref>PMID:11943163</ref> <ref>PMID:19225519</ref> <ref>PMID:19901339</ref> The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.<ref>PMID:9168929</ref> <ref>PMID:11544248</ref> <ref>PMID:11943163</ref> <ref>PMID:19225519</ref> <ref>PMID:19901339</ref> N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).<ref>PMID:9168929</ref> <ref>PMID:11544248</ref> <ref>PMID:11943163</ref> <ref>PMID:19225519</ref> <ref>PMID:19901339</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	One of the hallmarks of Alzheimer's disease (AD) are deposits of amyloid-beta (Abeta) protein in amyloid plaques in the brain. The Abeta peptide exists in several forms, including full-length Abeta1-42 and Abeta1-40 - and the N-truncated species, pyroglutamate Abeta3-42 and Abeta4-42, which appear to play a major role in neurodegeneration. We previously identified a murine antibody (TAP01), which binds specifically to soluble, non-plaque N-truncated Abeta species. By solving crystal structures for TAP01 family antibodies bound to pyroglutamate Abeta3-14, we identified a novel pseudo beta-hairpin structure in the N-terminal region of Abeta and show that this underpins its unique binding properties. We engineered a stabilised cyclic form of Abeta1-14 (N-Truncated Amyloid Peptide AntibodieS; the 'TAPAS' vaccine) and showed that this adopts the same 3-dimensional conformation as the native sequence when bound to TAP01. Active immunisation of two mouse models of AD with the TAPAS vaccine led to a striking reduction in amyloid-plaque formation, a rescue of brain glucose metabolism, a stabilisation in neuron loss, and a rescue of memory deficiencies. Treating both models with the humanised version of the TAP01 antibody had similar positive effects. Here we report the discovery of a unique conformational epitope in the N-terminal region of Abeta, which offers new routes for active and passive immunisation against AD.
		+
		+	Discovery of a novel pseudo beta-hairpin structure of N-truncated amyloid-beta for use as a vaccine against Alzheimer's disease.,Bakrania P, Hall G, Bouter Y, Bouter C, Beindorff N, Cowan R, Davies S, Price J, Mpamhanga C, Love E, Matthews D, Carr MD, Bayer TA Mol Psychiatry. 2022 Feb;27(2):840-848. doi: 10.1038/s41380-021-01385-7. Epub , 2021 Nov 15. PMID:34776512<ref>PMID:34776512</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 7oxn" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Hall, G, Cowan, R,~~ Carr, MD]]	+	[[Category: Carr MD]]
		+	[[Category: Cowan R]]
		+	[[Category: Hall G]]

OCA at 07:26, 29 June 2022

OCA — Wed, 29 Jun 2022 07:26:08 GMT

←Older revision		Revision as of 07:26, 29 June 2022
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry 7oxn is ON HOLD until Paper Publication~~	+	==Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide==
-		+	<StructureSection load='7oxn' size='340' side='right'caption='[[7oxn]]' scene=''>
-	~~Authors: Hall, G., Cowan, R., Carr, M.D.~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7OXN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7OXN FirstGlance]. <br>
-	~~Description:~~ Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7oxn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7oxn OCA], [https://pdbe.org/7oxn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7oxn RCSB], [https://www.ebi.ac.uk/pdbsum/7oxn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7oxn ProSAT]</span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	</table>
-	[[~~Category~~: ~~Cowan~~, R]]	+	__TOC__
-	[[Category: ~~Hall, G~~]]	+	</StructureSection>
-	[[Category: Carr, ~~M.D~~]]	+	[[Category: Large Structures]]
		+	[[Category: Hall, G, Cowan, R, Carr, MD]]

OCA at 07:53, 21 July 2021

OCA — Wed, 21 Jul 2021 07:53:34 GMT

←Older revision		Revision as of 07:53, 21 July 2021
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 7oxn is ON HOLD	+	The entry 7oxn is ON HOLD until Paper Publication

	Authors: Hall, G., Cowan, R., Carr, M.D.		Authors: Hall, G., Cowan, R., Carr, M.D.

OCA: Protected "7oxn" [edit=sysop:move=sysop]

OCA — Fri, 02 Jul 2021 02:35:58 GMT

Protected "7oxn" [edit=sysop:move=sysop]

←Older revision

Revision as of 02:35, 2 July 2021

OCA: New page: '''Unreleased structure''' The entry 7oxn is ON HOLD Authors: Hall, G., Cowan, R., Carr, M.D. Description: Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide [[Ca...

OCA — Fri, 02 Jul 2021 02:35:57 GMT

New page: '''Unreleased structure''' The entry 7oxn is ON HOLD Authors: Hall, G., Cowan, R., Carr, M.D. Description: Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide [[Ca...

New page

'''Unreleased structure'''

The entry 7oxn is ON HOLD

Authors: Hall, G., Cowan, R., Carr, M.D.

Description: Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide
[[Category: Unreleased Structures]]
[[Category: Cowan, R]]
[[Category: Hall, G]]
[[Category: Carr, M.D]]

7oxn - Revision history

OCA at 12:58, 1 February 2024

OCA at 07:26, 29 June 2022

OCA at 07:53, 21 July 2021

OCA: Protected "7oxn" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 7oxn is ON HOLD Authors: Hall, G., Cowan, R., Carr, M.D. Description: Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide [[Ca...